FDA-Approved Peptides for Weight and Metabolic Health

When patients ask about peptides for weight loss or metabolic health, the conversation almost always returns to one foundational question: which peptides are actually FDA-approved, and which are something else? The distinction matters because it shapes everything downstream — clinical evidence base, manufacturing controls, labeled indications, and how a licensed clinician can reasonably prescribe.

This article walks through the FDA-approved peptide medications used in weight and metabolic medicine, explains how they fit together as a class, and clarifies how prescribing decisions are made when a patient is evaluated for therapy.

What "FDA-approved" actually means in this category

An FDA-approved medication has gone through phased clinical trials, met the agency's safety and efficacy standards for at least one specific indication, and is manufactured under federal cGMP rules at facilities subject to inspection. The drug carries a prescribing label that defines:

• Approved indication (for example, chronic weight management or type 2 diabetes)
• Patient eligibility criteria (often a BMI threshold, with or without weight-related comorbidities)
• Recommended dose, titration schedule, and maximum dose
• Contraindications, warnings, and monitoring requirements

A peptide that is FDA-approved for one indication is not automatically appropriate for every patient. The label is a regulatory floor; clinical judgment, individual history, and risk-benefit analysis live on top of it.

The two FDA-approved peptide classes for metabolic health

Almost every FDA-approved peptide currently used in weight and metabolic medicine sits in one of two related families. Both work on the body''s incretin system — the gut hormones that help regulate insulin release, glucagon, gastric emptying, and satiety after meals.

GLP-1 receptor agonists

GLP-1 (glucagon-like peptide-1) receptor agonists mimic the action of native GLP-1, a hormone released by intestinal L-cells after a meal. Pharmacologic GLP-1 analogs:

• Stimulate glucose-dependent insulin secretion
• Suppress inappropriate glucagon release
• Slow gastric emptying, prolonging satiety after meals
• Act centrally on appetite-regulating regions of the brain

Multiple GLP-1 receptor agonist molecules have FDA approval. Some carry approvals for type 2 diabetes only; others are separately approved for chronic weight management at different doses. Available formulations include once-daily injection, once-weekly injection, and one orally administered option.

Dual GIP/GLP-1 receptor agonists

The dual incretin class adds activity at the GIP (glucose-dependent insulinotropic polypeptide) receptor on top of GLP-1 activity. The clinical rationale is that combined incretin agonism produces greater weight loss and glycemic improvement than GLP-1 monotherapy in head-to-head trials. As of 2026, this class has FDA approval for both type 2 diabetes and chronic weight management.

How clinicians decide whether a patient is a candidate

Eligibility is not a single number; it is a layered clinical evaluation.

1. Indication fit. Most FDA-approved metabolic peptides require either:

• A BMI of 30 or greater, or
• A BMI of 27 or greater with at least one weight-related comorbidity (such as hypertension, dyslipidemia, sleep apnea, or type 2 diabetes), or
• A diagnosis of type 2 diabetes for the diabetes-indicated forms.

2. Contraindication review. These medications carry specific contraindications, most notably a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Pregnancy is also a contraindication for chronic weight management indications.

3. Comorbid risk assessment. History of pancreatitis, severe gastroparesis, gallbladder disease, severe renal impairment, and certain psychiatric histories all influence whether — and which — peptide is appropriate.

4. Lab baseline. Most clinicians order at minimum a comprehensive metabolic panel, lipid panel, HbA1c, and TSH before initiating therapy, with additional labs depending on history.

5. Goal alignment. A patient seeking aggressive weight loss has different needs than a patient seeking metabolic improvement, microdose-style appetite control, or body recomposition. The labeled dose schedule was designed for the trial endpoints, not for every individual goal.

Microdosing FDA-approved peptides: what is and is not on-label

Some patients ask about lower-than-labeled doses of FDA-approved peptides — sometimes called microdosing. A few clarifications matter here:

• The labeled titration was selected to maximize efficacy in trial populations. It is not the only dose at which the medication has biological effect.
• Lower doses may produce milder appetite suppression and fewer GI side effects, which some patients prefer for tolerability or for body-recomposition goals.
• Prescribing below the labeled starting dose, or pausing at a lower maintenance dose than the trial endpoint, falls under clinical discretion and should be documented as such.

Microdosing is a clinical pattern, not a different drug. The decision belongs to the prescribing clinician working with the individual patient.

Compounded versions: an important distinction

When a brand-name FDA-approved peptide is on a federal shortage list, compounding pharmacies operating under FDA section 503A or 503B may legally prepare patient-specific compounded versions of the active ingredient. Patients should understand:

• Compounded medications are not themselves FDA-approved, even when the active ingredient is.
• They are legal during a documented shortage and when prescribed for an individual patient by a licensed clinician.
• The quality standards for 503A and 503B differ; reputable telehealth providers work only with state-licensed pharmacies that disclose their certifications.
• When the shortage resolves, the legal pathway for compounded versions narrows significantly.

This is one of the most commonly misunderstood areas of peptide care. A compounded version of an FDA-approved active ingredient is not the same product, even if it contains the same molecule.

Side effects and what to expect during titration

The dominant side effect profile across FDA-approved metabolic peptides is gastrointestinal:

• Nausea — most common, especially in the first 4 to 8 weeks and after each dose increase. Slow titration, smaller meals, and hydration help most patients.
• Constipation — frequent due to slowed gastric emptying. Fiber intake, magnesium, and adequate water typically manage it.
• Reflux — sometimes worsened; positional and dietary adjustments help, occasional acid-suppression therapy may be added.
• Fatigue — often reflects under-eating during dose escalation. Adequate protein and total calories matter.
• Injection-site reactions — usually mild and self-resolving.

Less common but clinically important: pancreatitis (rare, requires discontinuation), gallbladder events (more likely with rapid weight loss), hypoglycemia (mainly when combined with insulin or sulfonylureas), and rare hypersensitivity reactions.

What good follow-up looks like

A licensed program treating these peptides as serious medications — rather than as shipped boxes — typically includes:

• A structured intake with full medical, surgical, medication, and family history
• Baseline labs and a documented BMI and weight history
• A titration plan with explicit decision points for slowing, pausing, or stepping down
• Regular check-ins (weekly to monthly early on, less frequently once stable)
• Updated labs at intervals appropriate to the patient
• Lifestyle support — protein-forward nutrition, resistance training, sleep — because medication without behavior change leaves muscle and metabolic gains on the table

This is the difference between metabolic peptide therapy as a long-term clinical relationship and metabolic peptide therapy as a transactional purchase. The medications are the same; the outcomes are not.

How to think about choosing a peptide

There is no single best peptide. The right choice for a given patient depends on:

• Primary clinical goal (glycemic control, weight loss, recomposition, metabolic risk reduction)
• Tolerability history with prior medications
• Coexisting conditions and contraindications
• Insurance landscape and ability to pay
• Practical preferences (injection frequency, oral option availability)

A licensed clinician''s role is to translate those variables into a specific molecule, dose, and titration plan, then iterate based on the patient''s response.

Key takeaways

• FDA-approved peptides for weight and metabolic health currently belong to two related classes: GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists.
• Approval applies to specific indications, doses, and patient populations — not to every imaginable use.
• Compounded versions of these molecules exist legally during shortages but are regulatorily distinct from the FDA-approved products.
• Eligibility is a clinical evaluation, not a checkbox: BMI, comorbidities, contraindications, labs, and goals all matter.
• Side effects are mostly gastrointestinal and dose-related, and good titration plus structured follow-up dramatically improves the experience.

Patients who are evaluating telehealth peptide therapy should look for programs that treat these medications with the seriousness they deserve: a real intake, real labs, real follow-up, and a clinician who can adjust the plan to the patient instead of the other way around.